Back to results
US 10,119,169 B2Granted
Methods to diagnose and treat mullerian adenosarcoma
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsBrooke Howitt, Bradley Quade, Marisa Nucci, Lynette Sholl
Life of this patent
Estimating the term…
Abstract
Methods for diagnosing and treating Müllerian Adenosarcoma that include detecting the presence of one or more of a mutation in an ATRX gene, and/or a Copy Number Variation (CNV) in a MYBL1, MDM2, HMGA2, and/or CDK4 gene.
Claims5
A method of treating a subject who has Müllerian Adenosarcoma (MA), the method comprising:
- obtaining a sample comprising cells from the MA in a subject;
- performing an assay to determine the copy number of each of a MYBL1, MDM2, and CDK4 gene;
- comparing the copy number of the MYBL1, MDM2, and CDK4 genes to reference copy number that represents a copy number in a normal cell;
- detecting a copy number gain in a MYBL1, MDM2, or CDK4 gene as compared to the reference copy number;
- and
- administering to a subject who has a copy number gain or loss in a MYBL1 or CDK4 gene, or a copy number gain in a MDM2 gene as compared to the reference copy number a treatment comprising one or more of radical surgical resection;
- administration of radiotherapy;
- or administration of chemotherapy.
5 more elements
A method of treating a subject who has Mullerian Adenosarcoma (MA), the method comprising:
- obtaining a sample comprising cells from the MA in the subject;
- performing an assay to determine copy number of a MYBL1 gene;
- comparing the copy number of the MYBL1 gene to a reference copy number that represents a MYBL1 copy number in a normal cell;
- detecting a copy number gain in MYBL1 gene as compared to the reference copy number;
- and
- administering to a subject who has a copy number gain in a MYBL1 gene as compared to the reference copy number a treatment comprising an MYBL1 inhibitor, wherein the MYBL1 inhibitor is mexicanin I.
3 more elements
Dependencies are inferred from the claim text.